Blood Cancer Drug Discoveries

What the Future Holds

Publication Date	April 2008
Publisher	Espicom
Product Type	Report
Pages	245
ISBN Number	978-1-85822-314-8
Product Code	ESP00481

Price

£1,295.00
approximately: $1,923 | €1,524

PDF

Order above formats by FAX

Summary

This New Strategic Report from Espicom Provides A Comprehensive Review of Current and Future Treatments for Major Blood Cancer Therapy Areas: Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia, Acute Myeloid Leukaemia, Multiple Myeloma and Non-Hodgkin's Lymphoma.

Over 275 Pages of Product Analysis, Market Statistics and Forecasts Unique Market Share and 5-Year Sales Forecasts for Leading Products & Pipeline Prospects A Comprehensive Examination of Major Blood Cancer Therapy Areas Critical Competitive Evaluation and Scoring of Current and Future Products.

Providing...

Detailed Analysis and 5-Year Forecasts for Current Leading Products by Value
A Detailed Review and Assessment of up and Coming Products
Unique Product Assessment and Scoring
An Evaluation of The Current Understanding of Blood Cancers

Major Areas Covered

Chronic Lymphocytic Leukaemia
Chronic Myeloid Leukaemia
Acute Myeloid Leukaemia
Multiple Myeloma
Non-Hodgkin's Lymphoma

The Report Covers Major Blood Cancer Areas

Chronic Lymphocytic Leukaemia
Chronic Myeloid Leukaemia
Acute Myeloid Leukaemia
Multiple Myeloma
Non-Hodgkin's Lymphoma

The Market

Risk Factors, How The Disease Affects Patients, Diagnosis and Stages of The Disease
The Market in 2007 and 2012
Growth Drivers and Dampeners

Patient Statistics

Prevalence
Diagnosis Rates
Unmet Clinical Need

Current Treatment Options

Interventions by Type
Unique Five Point Competitive Assessment and Scoring of Current Therapies and Companies Involved
5-Year Sales Forecasts for Key Products

R&d: Drugs in Late Stage Development

Focus on New Classes of Drugs and The Companies Involved
Unique Competitive Assessment and Scoring of New Therapies and Companies Involved
5-Year Sales Forecasts for Key Products from Year of Launch

Extensive Tables and Charts

Content

Blood Cancers
- US Incidence of Blood Cancers, 2007
Unmet Medical Need
New Agents in Development
- New Mechanisms of Action under Investigation for The Development of Blood Cancers:
- Monoclonal Antibodies in Development for Treatment of Blood Cancers
Major Players
- 2007
- Market Share of Players in The Worldwide Blood Cancers Market, 2007
- 2012
- Market Share of Players in The Worldwide Blood Cancers Market, 2012
Global Sales
- Estimated and Forecast Worldwide Sales in The Treatment of Blood Cancers (US$ Millions)
- Regional Breakdown of Blood Cancer Market by Sales - 2007 and 2012
Chronic Lymphocytic Leukaemia
Background
Patient Statistics
- Patient Model
- Estimated Prevalence of Cll in Major Markets, 2005-2012
Drug Growth Drivers
Drug Growth Dampeners
The Market
- Global Market
- Forecast Cll Market Growth (US$ Millions)
- Major Players
- Current Drugs Commonly Used in The Treatment of Cll
- Major Players in Cll by Sales - 2007
- Forecast Major Players in Cll by Sales - 2012
The Drugs
Current Drugs
- Selected Response Rates from Studies of First Line Treatment of Cll:
Fludara
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Fludara Sales in Cll by Region (US$ Millions)
- Forecast Fludara Sales in Cll by Use (US$ Millions)
- Competitor Ratio Analysis
Rituxan
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Blood Cancer Drug Discoveries: What The Future Holds
- Sales Forecasts and Assumptions
- Forecast Rituxan Sales in Cll by Use (US$ Millions)
- Forecast Rituxan Sales in Cll by Region (US$ Millions)
- Competitor Ratio Analysis
Campath
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Campath Sales in Cll by Use (US$ Millions)
- Competitor Ratio Analysis
Agents in Development
- Drugs in Development for The Treatment of Cll
- Agents in Late Stage Development for Cll:
Treanda
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Treanda Sales in Cll (US$ Millions)
- Competitor Ratio Analysis
Genasense
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Genasense in Cll Efficacy Summary:
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Genasense Sales in Cll by Region (US$ Millions):
- Forecast Genasense Sales in Cll by Use (US$ Millions):
- Competitor Ratio Analysis
Ofatumumab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Ofatumumab Sales in Cll by Region (US$Millions):
- Forecast Ofatumumab Sales in Cll by Use (US$Millions):
- Competitor Ratio Analysis
Alvocidib
- Blood Cancer Drug Discoveries: What The Future Holds
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Alvocidib Sales in Cll (US$ Millions)
- Competitor Ratio Analysis
Lumliximab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Lumiliximab Sales in Cll (US$ Millions)
- Competitor Ratio Analysis
Revlimid
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Revlimid Cll Sales by Use (US$ Millions):
- Forecast Revlimid Cll Sales by Region (US$ Millions):
- Competitor Ratio Analysis
Chronic Myeloid Leukaemia
Background
Patient Statistics
- Trends in US Cml Incidence:
- Estimated Incidence in Worldwide Cml Prevalence:
Drug Growth Drivers
Drug Growth Dampeners
The Market
- Global Market
- Forecast Worldwide Cml Market (US$ Millions)
- Major Players - 2007
- Major Players in Cml by Sales - 2007
- Major Players - 2012
- Forecast Major Players in Cll by Sales - 2012
The Drugs
- Cml Treatment Timeline:
- Current Drugs
- Current Drugs Used in The Treatment of Cml:
Gleevec/Glivec
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Blood Cancer Drug Discoveries: What The Future Holds
- Iris Study: 18-Month Response Rates Determined by Intent-to-Treat Analysis
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Gleevec Sales in Cml (US$ Millions) - Excludes Sales in Gist
- Competitor Ratio Analysis
Sprycel
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Sprycel Cml Sales (US$ Millions):
- Competitor Ratio Analysis
Tasigna
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Tasigna Cml Sales Forecast (US$ Millions)
- Competitor Ratio Analysis
Agents in Development
- Drugs in Development for The Treatment of Cml:
- Agents in Late Stage Development for Cml:
Bosutinib
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Bosutinib Sales in Cml (US$ Millions)
- Competitor Ratio Analysis
Panobinostat
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
Mk-0457/ Vx 680
- Blood Cancer Drug Discoveries: What The Future Holds
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
Acute Myeloid Leukaemia
Background
- French-American-British (Fab) Classification of Aml
- Who Aml Classification:
- Selected Risk Factors Associated with Aml:
- Common Chromosomal Abnormalities in Aml:
Patient Statistics
- Forecast Incidence of Aml by Region:
Drug Growth Drivers
Drug Growth Dampeners
The Market
- Global Market
- Forecast Worldwide Adult Aml Market
- Major Players - 2007
- Major Players - 2012
- Forecast Major Players in Aml by Sales - 2012
The Drugs
- Treatment Nave Patients
- Relapsed & Refractory Aml
- Current Drugs Used in The Treatment of Aml:
- Therapeutic Strategies in Aml and Relapsed/Refractory Aml:
Mylotarg
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Summary of Response Rates in Mylotarg Studies:
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
Agents in Development
- Agents in Late Stage Development for Aml:
Clolar/Evoltra
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Sales of Clolar/Evoltra in Adult Aml (US$ Millions):
- Competitor Ratio Analysis
- Blood Cancer Drug Discoveries: What The Future Holds
Cloretazine
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Sales of Cloretazine in Aml (US$ Millions)
- Competitor Ratio Analysis
Zarnestra
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
Dacogen
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Dacogen Sales in Adult Aml (US$ Millions)
- Competitor Ratio Analysis
Lestaurtinib
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Lestaurtinib Sales in Aml (US$ Millions)
- Competitor Ratio Analysis
Midostaurin
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Midostaurin Sales in Aml (US$ Millions)
- Competitor Ratio Analysis
Tandutinib
- Novelty/Rationale for Mechanism of Action
- Blood Cancer Drug Discoveries: What The Future Holds
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
Zosuquidar
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
Xanafide
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Xanafide Sales in Aml (US$ Millions)
- Competitor Ratio Analysis
Ceplene
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Ceplene Sales in Aml (US$ Millions)
- Competitor Ratio Analysis
Multiple Myeloma
Background
Patient Statistics
- Patient Model
- Estimated Prevalence of Multiple Myeloma in Selected Markets
Drug Growth Drivers
Drug Growth Dampeners
The Market
- Global Market
- Forecast Worldwide Multiple Myeloma Market (US$ Millions):
- Major Players
- Major Players in Multiple Myeloma by Sales - 2007
- Major Players in Multiple Myeloma by Sales - 2012
- Current Drugs Used in The Treatment of Multiple Myeloma:
The Drugs
- Blood Cancer Drug Discoveries: What The Future Holds
Thalomid
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Thalomid Sales in Multiple Myeloma (US$ Millions)
- Competitor Ratio Analysis
Revlimid
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Data Summary of Mm-009 and Mm - 010 Studies:
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Front Line Myeloma Comparison:
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
Velcade
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Velcade Sales in Multiple Myeloma (US$ Millions)
- Competitor Ratio Analysis
Agents in Development
- Drugs in Development for The Treatment of Multiple Myeloma:
- Agents in Late Stage Development for Multiple Myeloma:
Tanespimycin
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Tanespimycin Sales in Relapsed/Refractory Multiple Myeloma (US$ Millions)
- Competitor Ratio Analysis
Mapatumumab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Blood Cancer Drug Discoveries: What The Future Holds
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
Belinostat
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
Perifosine
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
Carfilzomib
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
Non Hodgkin's Lymphoma
Background
- Frequency of Nhl Subtypes in Adults:
- 1) B-Cell Cll/Small Lymphocytic Lymphoma
- 2) Marginal Zone Lymphoma
- 3) Lymphoplasmocytic Lymphoma (Waldenstrom Macroglobulinemia):
- 4) Follicular Lymphoma:
- 1) Cutaneous T-Cell Lymphoma:
- 1) Diffuse Large B-Cell Lymphoma (Dlbcl):
- 2) Mantle Cell Lymphoma:
- 3) Burkitt Lymphoma/Burkitt-like Lymphoma:
- 4) Precursor B-Cell Leukaemia/Lymphoma
- 1) Anaplastic Large T/Null-Cell Lymphoma:
- 2) Precursor T-Lymphoblastic Lymphoma/Leukaemia:
- 3) Peripheral T-Cell Lymphomas:
Staging Systems
Patient Statistics
- Patient Model
- Forecast Nhl Incidence and Prevalence (000s)
Drug Growth Drivers
Drug Growth Dampeners
The Market
- Blood Cancer Drug Discoveries: What The Future Holds
- Global Market
- Forecast Nhl Market (Excluding Ctcl) - US$ Millions
- Forecast Ctcl Market - US$ Millions
- Major Players
- Current Drugs Commonly Used in The Treatment of Nhl
- Major Players in Nhl by Sales - 2007
- Major Players in Nhl by Sales - 2012
The Drugs
- Low Grade or Indolent Nhl
- Treatment Options in Indolent/Low-Grade Nhl:
- Intermediate- and High-Grade Lymphomas:
- T-Cell Lymphomas:
- Summary of Common Therapies in Nhl
Marketed Agents for Use in Nhl
Rituxan
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Rituxan Penetration Rates, Q3-Q4 2005
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Rituxan Sales in Nhl Indications by Region (US$ Millions)
- Forecast Rituxan Sales in Nhl Indications by Use (US$ Millions)
- Competitor Ratio Analysis
Fludara
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Fludara Sales in Nhl Indications (US$ Millions)
- Competitor Ratio Analysis
Bexxar
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Bexxar Sales (US$ Millions):
- Competitor Ratio Analysis
Zevalin
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Blood Cancer Drug Discoveries: What The Future Holds
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Zevalin Sales (US$ Millions)
- Competitor Ratio Analysis
Marketed Agents for Cutatenous T-Cell Lymphoma
Zolinza
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Zolinza Sales in Ctcl (US$ Millions)
- Competitor Ratio Analysis
Agents in Development
- Drugs in Development for The Treatment of Nhl:
- Agents in Late Stage Development for Nhl:
Treanda
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Treanda US Sales Forecasts in Nhl Indication (US$ Millions)
- Competitor Ratio Analysis
Ofatumumab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Phase I/Ii Trial Results Summary:
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Sales of Ofatumumab in Nhl by Region (US$ Millions):
- Forecast Sales of Ofatumumab in Nhl by Use (US$ Millions):
- Competitor Ratio Analysis
Galiximab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Galiximab Sales in Nhl (US$ Millions)
- Competitor Ratio Analysis
- Blood Cancer Drug Discoveries: What The Future Holds
Pixantrone
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Pixantrone Nhl Sales by Region (US$ Millions):
- Forecast Pixantrone Sales in Nhl by Use (US$ Millions)
- Competitor Ratio Analysis
Revlimid
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Revlimid Sales Forecasts in Nhl (US$ Millions)
- Competitor Ratio Analysis
Torisel
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Torisel Sales in Mcl (US$ Millions)
- Competitor Ratio Analysis
Velcade
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Velcade Sales in Mcl (US$ Millions)
- Forecast Velcade Sales in Follicular Nhl (Excludes Mcl) by Region (US$ Millions)
- Forecast Velcade Sales in Follicular Nhl (Excludes Mcl) by Use (US$ Millions)
- Competitor Ratio Analysis
Inotuzumab Ozogamicin
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Blood Cancer Drug Discoveries: What The Future Holds
- Competitor Ratio Analysis
Agents in Late Stage Development for Cutaneous T-Cell Lymphoma
Zanliumumab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Sales of Zanolimumab in Ctcl (US$ Millions)
- Competitor Ratio Analysis
Belinostat
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Sales of Belinostat in Ctcl (US$ Millions)
- Competitor Ratio Analysis
Fodosine
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Sales of Fodosine in Ctcl (US$ Millions)
- Competitor Ratio Analysis
Epratuzumab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
Enzastaurin
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
Cra Analysis: Aml
- Blood Cancer Drug Discoveries: What The Future Holds
- Cra Summary
Cra Analysis: Cml
- Cra Summary
Cra Analysis: Cll
Cra Analysis: Multiple Myeloma
- Cra Summary
Cra Analysis: Nhl
- Cra Analysis - Nhl
- Cra Analysis - Nhl (Continued)...includes Ctcl
Acronyms